To prevent such activation in patients suffering from Alzheimer’s disease, inhibition of NLRP3 and NLRP1 has been found to be promising as it promotes non-phlogistic clearance of amyloid-β and improves cognitive functions [224, 225]. Here, NLRP3 is linked to early-onset autosomal dominant Alzheimer disease.